{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:44:35Z","timestamp":1750344275973},"reference-count":49,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Research Foundation\/Department of Science and Technology: South African Research Chair Initiative Program and Medical Research Council of South Africa"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.vaccine.2017.02.025","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T12:49:34Z","timestamp":1487854174000},"page":"4457-4460","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"PA","title":["Prospects for preventing infant invasive GBS disease through maternal vaccination"],"prefix":"10.1016","volume":"35","author":[{"given":"Shabir A.","family":"Madhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyaad","family":"Dangor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10053","key":"10.1016\/j.vaccine.2017.02.025_b0005","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(16)31575-6","article-title":"Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2017.02.025_b0010","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/adc.2008.148874","article-title":"Group B streptococcal disease in infants: a case control study","volume":"94","author":"Heath","year":"2009","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.vaccine.2017.02.025_b0015","doi-asserted-by":"crossref","first-page":"e0123014","DOI":"10.1371\/journal.pone.0123014","article-title":"Burden of invasive group B Streptococcus disease and early neurological sequelae in South African infants","volume":"10","author":"Dangor","year":"2015","journal-title":"PLoS ONE"},{"issue":"17","key":"10.1016\/j.vaccine.2017.02.025_b0020","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1001\/jama.299.17.2056","article-title":"Epidemiology of invasive group B streptococcal disease in the United States, 1999\u20132005","volume":"299","author":"Phares","year":"2008","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.vaccine.2017.02.025_b0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/pch\/4.7.465","article-title":"Relationship between antenatal group B streptococcal vaginal colonization and premature labour","volume":"4","author":"Allen","year":"1999","journal-title":"Paediatr Child Health"},{"issue":"12","key":"10.1016\/j.vaccine.2017.02.025_b0030","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/apa.12764","article-title":"Meta-analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications","volume":"103","author":"Bakhuizen","year":"2014","journal-title":"Acta Paediatr"},{"issue":"9815","key":"10.1016\/j.vaccine.2017.02.025_b0035","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(11)61651-6","article-title":"Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis","volume":"379","author":"Edmond","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2017.02.025_b0040","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1473-3099(16)30055-X","article-title":"Prevalence of maternal colonisation with group B streptococcus: a systematic review and meta-analysis","volume":"16","author":"Kwatra","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"RR-10","key":"10.1016\/j.vaccine.2017.02.025_b0045","first-page":"1","article-title":"Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010","volume":"59","author":"Verani","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"9705","key":"10.1016\/j.vaccine.2017.02.025_b0050","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(09)61339-8","article-title":"Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial","volume":"374","author":"Cutland","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2017.02.025_b0055","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1542\/peds.2011-1548","article-title":"Maternal HIV infection and vertical transmission of pathogenic bacteria","volume":"130","author":"Cutland","year":"2012","journal-title":"Pediatrics"},{"issue":"1 Pt 1","key":"10.1016\/j.vaccine.2017.02.025_b0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1542\/peds.105.1.21","article-title":"Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study","volume":"105","author":"Schuchat","year":"2000","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2017.02.025_b0065","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1086\/605473","article-title":"Population-based incidence and etiology of community-acquired neonatal bacteremia in Mirzapur, Bangladesh: an observational study","volume":"200","author":"Darmstadt","year":"2009","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2017.02.025_b0070","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.inf.0000078163.80807.88","article-title":"Predictors of neonatal sepsis in developing countries","volume":"22","author":"Weber","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2017.02.025_b0075","doi-asserted-by":"crossref","first-page":"e0152524","DOI":"10.1371\/journal.pone.0152524","article-title":"Invasive Group B streptococcal disease in South Africa: importance of surveillance methodology","volume":"11","author":"Quan","year":"2016","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.vaccine.2017.02.025_b0080","doi-asserted-by":"crossref","first-page":"16067","DOI":"10.1038\/nmicrobiol.2016.67","article-title":"Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya","volume":"1","author":"Seale","year":"2016","journal-title":"Nat Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2017.02.025_b0085","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/1471-0528.13527","article-title":"Maternal group B streptococcus-related stillbirth: a systematic review","volume":"122","author":"Nan","year":"2015","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.vaccine.2017.02.025_b0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0020-7292(96)02705-1","article-title":"Stillbirths and intrauterine infection, histologic chorioamnionitis and microbiological findings","volume":"54","author":"Moyo","year":"1996","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2017.02.025_b0095","doi-asserted-by":"crossref","first-page":"D20","DOI":"10.1016\/j.vaccine.2012.11.056","article-title":"Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine","volume":"31","author":"Schrag","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2017.02.025_b0100","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/AOG.0000000000000163","article-title":"Early-onset group B streptococcal disease in the United States: potential for further reduction","volume":"123","author":"Verani","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"14","key":"10.1016\/j.vaccine.2017.02.025_b0105","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJM197604012941404","article-title":"Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection","volume":"294","author":"Baker","year":"1976","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2017.02.025_b0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/14760584.2014.953939","article-title":"Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants","volume":"14","author":"Dangor","year":"2015","journal-title":"Expert Rev Vacc"},{"issue":"48","key":"10.1016\/j.vaccine.2017.02.025_b0115","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1016\/j.vaccine.2015.10.019","article-title":"Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants","volume":"33","author":"Dangor","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2017.02.025_b0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.0006-341X.2001.00135.x","article-title":"Bayesian inference on protective antibody levels using case-control data","volume":"57","author":"Carey","year":"2001","journal-title":"Biometrics"},{"issue":"5","key":"10.1016\/j.vaccine.2017.02.025_b0125","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/infdis\/jit549","article-title":"Maternal antibody at delivery protects neonates from early onset group B streptococcal disease","volume":"209","author":"Baker","year":"2014","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.02.025_b0130","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/cid\/ciw377","article-title":"The protective value of maternal group B streptococcus antibodies: quantitative and functional analysis of naturally acquired responses to capsular polysaccharides and pilus proteins in european maternal sera","volume":"63","author":"Fabbrini","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2017.02.025_b0135","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1086\/323350","article-title":"Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study","volume":"184","author":"Lin","year":"2001","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2017.02.025_b0140","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/422756","article-title":"Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen","volume":"190","author":"Lin","year":"2004","journal-title":"J Infect Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2017.02.025_b0145","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1056\/NEJM198811033191802","article-title":"Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus","volume":"319","author":"Baker","year":"1988","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2017.02.025_b0150","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1172\/JCI119042","article-title":"Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine","volume":"98","author":"Kasper","year":"1996","journal-title":"J Clin Invest"},{"issue":"24","key":"10.1016\/j.vaccine.2017.02.025_b0155","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1016\/S0264-410X(03)00353-0","article-title":"Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine","volume":"21","author":"Baker","year":"2003","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2017.02.025_b0160","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1473-3099(16)00152-3","article-title":"Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b\/2 trial","volume":"16","author":"Madhi","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2017.02.025_b0165","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(15)00484-3","article-title":"Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial","volume":"16","author":"Heyderman","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2017.02.025_b0170","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.vaccine.2016.02.044","article-title":"A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women","volume":"34","author":"Leroux-Roels","year":"2016","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2017.02.025_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/S1097-8690(07)71249-0","article-title":"Progress toward vaginal GBS vaccine is seen","volume":"40","author":"Mahoney","year":"2007","journal-title":"Internal Med News"},{"key":"10.1016\/j.vaccine.2017.02.025_b0180","series-title":"47th infectious diseases society of America annual meeting, Philadelphia","article-title":"Women receiving group B Streptococcus serotype III tetanus toxoid (GBS III-TT) vaccine have reduced vaginal and rectal acquisition of GBS type III","author":"Hillier","year":"2009"},{"issue":"6","key":"10.1016\/j.vaccine.2017.02.025_b0185","doi-asserted-by":"crossref","first-page":"568.e13","DOI":"10.1016\/j.cmi.2015.01.030","article-title":"Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women","volume":"21","author":"Kwatra","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2017.02.025_b0190","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/infdis\/jiw056","article-title":"Serotype-specific cell-mediated immunity associated with clearance of homotypic group B streptococcus rectovaginal colonization in pregnant women","volume":"213","author":"Kwatra","year":"2016","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2017.02.025_b0195","doi-asserted-by":"crossref","first-page":"e0169101","DOI":"10.1371\/journal.pone.0169101","article-title":"Temporal changes in invasive group B streptococcus serotypes: implications for vaccine development","volume":"11","author":"Dangor","year":"2016","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2017.02.025_b0200","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3201\/eid1904.121572","article-title":"Serotype IV and invasive group B streptococcus disease in neonates, Minnesota, USA, 2000\u20132010","volume":"19","author":"Ferrieri","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.02.025_b0205","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1084\/jem.177.6.1593","article-title":"Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections","volume":"177","author":"Stalhammar-Carlemalm","year":"1993","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2017.02.025_b0210","doi-asserted-by":"crossref","first-page":"F403","DOI":"10.1136\/adc.2005.090472","article-title":"Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection","volume":"91","author":"Larsson","year":"2006","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"4","key":"10.1016\/j.vaccine.2017.02.025_b0215","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.vaccine.2007.11.034","article-title":"Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease","volume":"26","author":"Pannaraj","year":"2008","journal-title":"Vaccine"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2017.02.025_b0220","doi-asserted-by":"crossref","first-page":"D52","DOI":"10.1016\/j.vaccine.2013.02.029","article-title":"Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants","volume":"31","author":"Madhi","year":"2013","journal-title":"Vaccine"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2017.02.025_b0225","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2017.02.025_b0230","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1586\/14760584.2016.1164046","article-title":"Influenza immunology evaluation and correlates of protection: a focus on vaccines","volume":"15","author":"Trombetta","year":"2016","journal-title":"Expert Rev Vacc"},{"issue":"23","key":"10.1016\/j.vaccine.2017.02.025_b0235","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/S0264-410X(03)00230-5","article-title":"Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants","volume":"21","author":"Jodar","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.025_b0240","unstructured":"World Health Organization. GBS vaccine research and development technical roadmap and WHO preferred product characteristics, Geneva, Switzerland 2016. Available at: http:\/\/www.who.int\/immunization\/research\/development\/ppc_groupb_strepvaccines\/en\/."},{"issue":"9930","key":"10.1016\/j.vaccine.2017.02.025_b0245","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(13)61682-7","article-title":"Use of vaccines as probes to define disease burden","volume":"383","author":"Feikin","year":"2014","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17302190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17302190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T17:33:53Z","timestamp":1530293633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17302190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":49,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0264410X17302190"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.02.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospects for preventing infant invasive GBS disease through maternal vaccination","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}